Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 4/2014

01-04-2014 | Original Paper

CEA/CA72-4 levels in peritoneal lavage fluid are predictive factors in patients with gastric carcinoma

Authors: Manabu Yamamoto, Keiji Yoshinaga, Ayumi Matsuyama, Shinichi Tsutsui, Teruyoshi Ishida

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2014

Login to get access

Abstract

Purpose

Increased levels of tumor marker in intra-operative peritoneal lavage are associated with an earlier detection of recurrent peritoneal dissemination.

Method

Intra-operative peritoneal lavage samples from 193 patients with gastric cancer were obtained to determine the levels of the tumor markers, carcinoembryonic antigen (CEA) and cancer-related antigen 72-4 (CA72-4) using a chemiluminescent enzyme immunoassay.

Results

The peritoneal lavage CEA (CY-CEA), CA72-4 (CY-CA72-4) and serosal invasion were independent factors predicting the peritoneal dissemination including CY(+). The patients were divided into four groups on the basis of peritoneal lavage tumor marker status; group A: CY-CEA (−), CY-CA72-4 (−) group (CEA < 0.5 ng/ml, CA72-4 < 1.3 U/ml); group B: CY-CEA (−), CY-CA72-4 (+) group (CEA < 0.5 ng/ml, CA72-4 ≥ 1.3 U/ml); group C: CY-CEA (+), CY-CA72-4 (−) group (CEA ≥ 0.5 ng/ml, CA72-4 < 1.3 U/ml); and group D: CY-CEA (+), CY-CA72-4 (+) group (CEA ≥ 0.5 ng/ml, CA72-4 ≥ 1.3 U/ml). The 5-year survival among the patients in groups A, B, C and D was 87, 68, 38 and 20 %, respectively (p < 0.0001).

Conclusion

Combined analysis of these markers is therefore considered to be helpful for accurately determining sites of recurrence and the prognosis in advanced gastric cancer patients.
Literature
go back to reference Asao T, Fukuda T, Yazawa S, Nagamachi Y (1991) Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer. Cancer 68:44–47CrossRefPubMed Asao T, Fukuda T, Yazawa S, Nagamachi Y (1991) Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer. Cancer 68:44–47CrossRefPubMed
go back to reference Byrne DJ, Browning MCK, Chschieri A (1990) CA72-4: a new tumor marker for gastric cancer. Br J Surg 77:1010–1013CrossRefPubMed Byrne DJ, Browning MCK, Chschieri A (1990) CA72-4: a new tumor marker for gastric cancer. Br J Surg 77:1010–1013CrossRefPubMed
go back to reference Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J (2012) Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 15:154–161CrossRefPubMed Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J (2012) Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 15:154–161CrossRefPubMed
go back to reference Fayed ST, Ahmad SM, Kassim SK, Khalifa A (1998) The value of CA125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis Markers 14:155–160CrossRefPubMedCentralPubMed Fayed ST, Ahmad SM, Kassim SK, Khalifa A (1998) The value of CA125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis Markers 14:155–160CrossRefPubMedCentralPubMed
go back to reference Fujimoto T, Zhang B, Minami S, Wang X, Takahashi Y, Mai M (2002) Evaluation of intraoperative intraperitoneal cytology for advanced gastric cancer. Oncology 62:201–208CrossRefPubMed Fujimoto T, Zhang B, Minami S, Wang X, Takahashi Y, Mai M (2002) Evaluation of intraoperative intraperitoneal cytology for advanced gastric cancer. Oncology 62:201–208CrossRefPubMed
go back to reference Hamazoe R, Maeta M, Matsui T, Shibata S, Shiota S, Kaibara N (1992) CA72-4 compared with carcinoembryonic antigen as a tumor marker for gastric cancer. Eur J Cancer 28(8–9):1351–1354CrossRef Hamazoe R, Maeta M, Matsui T, Shibata S, Shiota S, Kaibara N (1992) CA72-4 compared with carcinoembryonic antigen as a tumor marker for gastric cancer. Eur J Cancer 28(8–9):1351–1354CrossRef
go back to reference Ikeguchi M, Katano K, Saitou H, Tsujitani S, Maeta M, Kaibara N (1997) Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterol 44:866–871 Ikeguchi M, Katano K, Saitou H, Tsujitani S, Maeta M, Kaibara N (1997) Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterol 44:866–871
go back to reference Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS et al (2011) The relationships between perioperative CEA, CA19-9, and CA72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol 104:585–591CrossRefPubMed Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS et al (2011) The relationships between perioperative CEA, CA19-9, and CA72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol 104:585–591CrossRefPubMed
go back to reference Kiyasu Y, Kaneshima S, Koga S (1981) Morphogenesis of peritoneal metastasis in human gastric cancer. Cancer Res 41:1236–1239PubMed Kiyasu Y, Kaneshima S, Koga S (1981) Morphogenesis of peritoneal metastasis in human gastric cancer. Cancer Res 41:1236–1239PubMed
go back to reference Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M (1990) Serum carcinoembryonic antigen level increase correlate with tumor progression in patients with differentiated gastric carcinoma following non-curative resection. Cancer Res 50:3952–3955PubMed Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M (1990) Serum carcinoembryonic antigen level increase correlate with tumor progression in patients with differentiated gastric carcinoma following non-curative resection. Cancer Res 50:3952–3955PubMed
go back to reference Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K (2000) Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87:353–357CrossRefPubMed Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K (2000) Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87:353–357CrossRefPubMed
go back to reference Moore GE, Sako K, Kondo T, Badillo J, Burke E (1961) Assessment of the exfoliation of tumor cells into the body cavities. Surg Gynecol Obstet 112:469–474PubMed Moore GE, Sako K, Kondo T, Badillo J, Burke E (1961) Assessment of the exfoliation of tumor cells into the body cavities. Surg Gynecol Obstet 112:469–474PubMed
go back to reference Nishiyama M, Takashima I, Tanaka T, Yoshida K, Toge T, Nagata N et al (1995) Carcinoembryonic antigen levels in the peritoneal cavity: useful guide to peritoneal recurrence and prognosis for gastric cancer. World J Surg 19:133–137CrossRefPubMed Nishiyama M, Takashima I, Tanaka T, Yoshida K, Toge T, Nagata N et al (1995) Carcinoembryonic antigen levels in the peritoneal cavity: useful guide to peritoneal recurrence and prognosis for gastric cancer. World J Surg 19:133–137CrossRefPubMed
go back to reference Paterson AJ, Schlom J, Sears HF, Bennett J, Colcher D (1986) A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72-3. Int J Cancer 37:659–666CrossRefPubMed Paterson AJ, Schlom J, Sears HF, Bennett J, Colcher D (1986) A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72-3. Int J Cancer 37:659–666CrossRefPubMed
go back to reference Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Warmer M et al (2002) Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 20:1049–1055CrossRefPubMed Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Warmer M et al (2002) Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 20:1049–1055CrossRefPubMed
go back to reference Sobin LH, Wittekind CH (1997) International Union Against Cancer: TNM classification of malignant tumors, 5th edn. Wiley, New York Sobin LH, Wittekind CH (1997) International Union Against Cancer: TNM classification of malignant tumors, 5th edn. Wiley, New York
go back to reference Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J et al (2011) Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol 37:312–318CrossRefPubMed Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J et al (2011) Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol 37:312–318CrossRefPubMed
go back to reference Sugarbeker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope of cure. Oncology 58:96–107CrossRef Sugarbeker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope of cure. Oncology 58:96–107CrossRef
go back to reference Washington K (2010) 7th Edition of the AJCC Cancer staging manual: stomach. Ann Surg Oncol 17:3077–3079CrossRefPubMed Washington K (2010) 7th Edition of the AJCC Cancer staging manual: stomach. Ann Surg Oncol 17:3077–3079CrossRefPubMed
go back to reference Yamamoto M, Baba H, Kakeji Y, Endo K, Ikeda Y, Toh Y et al (2004) Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer. Oncology 67:19–26CrossRefPubMed Yamamoto M, Baba H, Kakeji Y, Endo K, Ikeda Y, Toh Y et al (2004) Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer. Oncology 67:19–26CrossRefPubMed
go back to reference Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T (2006) The features of peritoneal dissemination with early gastric cancer. Surg Today 36(9):835–838CrossRefPubMed Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T (2006) The features of peritoneal dissemination with early gastric cancer. Surg Today 36(9):835–838CrossRefPubMed
go back to reference Yamamoto M, Baba H, Toh Y, Okamura T, Maehara Y (2007) Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol 133:471–476CrossRefPubMed Yamamoto M, Baba H, Toh Y, Okamura T, Maehara Y (2007) Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol 133:471–476CrossRefPubMed
go back to reference Yu W, Whang I, Suh I, Averbach A, Chang D, Sugerbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354CrossRefPubMedCentralPubMed Yu W, Whang I, Suh I, Averbach A, Chang D, Sugerbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354CrossRefPubMedCentralPubMed
Metadata
Title
CEA/CA72-4 levels in peritoneal lavage fluid are predictive factors in patients with gastric carcinoma
Authors
Manabu Yamamoto
Keiji Yoshinaga
Ayumi Matsuyama
Shinichi Tsutsui
Teruyoshi Ishida
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 4/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1601-y

Other articles of this Issue 4/2014

Journal of Cancer Research and Clinical Oncology 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.